Evidence map›Paper›PMID 25490247›Full record

ArticleAmerican journal of respiratory cell and molecular biology2015

Antiinflammatory and Antimicrobial Effects of Thiocyanate in a Cystic Fibrosis Mouse Model.

Joshua D Chandler, Elysia Min, Jie Huang, Cameron S McElroy, Nina Dickerhof, Tessa Mocatta, Ashley A Fletcher, Christopher M Evans, Liping Liang, Manisha Patel and 3 more

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Dual oxidase 1 promotes antiviral innate immunity.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Joshua D Chandler1 Department of Pharmaceutical Sciences and.
Elysia MinDepartments of 2 Medicine and.
Jie HuangDepartments of 2 Medicine and.
Cameron S McElroy1 Department of Pharmaceutical Sciences and.
Nina Dickerhof3 Centre for Free Radical Research, Department of Pathology, University of Otago Christchurch, Christchurch, New Zealand.
Tessa Mocatta3 Centre for Free Radical Research, Department of Pathology, University of Otago Christchurch, Christchurch, New Zealand.
Ashley A Fletcher4 Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, Colorado.
Christopher M Evans4 Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, Colorado.
Liping Liang1 Department of Pharmaceutical Sciences and.
Manisha Patel1 Department of Pharmaceutical Sciences and.
Anthony J Kettle3 Centre for Free Radical Research, Department of Pathology, University of Otago Christchurch, Christchurch, New Zealand.
David P NicholsDepartments of 2 Medicine and.
Brian J Day1 Department of Pharmaceutical Sciences and.
Pharmaceutical Biotechnology (Czechia) · CZUniversity of Otago · NZUniversity of Colorado Denver · USNational Jewish Health · US

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Role of Mucin in Lung Homeostasis and PathophysiologyR01HL080396 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Christopher M Evans · 2009 to 2026
$8.6M
Colorado Clinical and Translational Sciences InstituteKL2TR001080 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$2.6M
Fungal Exposure and the Respiratory Tract MicrobiomeR21ES023384 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI EVANS, CHRISTOPHER M · 2014 to 2016
$931k
Colorado Clinical and Translational Science Institute (KL2)KL2TR000156 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$521k
NCATS NIH HHS KL2 TR000156NCATS NIH HHS KL2 TR001080NCATS NIH HHS UL1 TR001082NHLBI NIH HHS R01 HL080396NHLBI NIH HHS R01 HL08469NIEHS NIH HHS R21 ES023384
6 · The paper itself

Abstract

Thiocyanate (SCN) is used by the innate immune system, but less is known about its impact on inflammation and oxidative stress. Granulocytes oxidize SCN to evolve the bactericidal hypothiocyanous acid, which we previously demonstrated is metabolized by mammalian, but not bacterial, thioredoxin reductase (TrxR). There is also evidence that SCN is dysregulated in cystic fibrosis (CF), a disease marked by chronic infection and airway inflammation. To investigate antiinflammatory effects of SCN, we administered nebulized SCN or saline to β epithelial sodium channel (βENaC) mice, a phenotypic CF model. SCN significantly decreased airway neutrophil infiltrate and restored the redox ratio of glutathione in lung tissue and airway epithelial lining fluid to levels comparable to wild type. Furthermore, in Pseudomonas aeruginosa-infected βENaC and wild-type mice, SCN decreased inflammation, proinflammatory cytokines, and bacterial load. SCN also decreased airway neutrophil chemokine keratinocyte chemoattractant (also known as C-X-C motif chemokine ligand 1) and glutathione sulfonamide, a biomarker of granulocyte oxidative activity, in uninfected βENaC mice. Lung tissue TrxR activity and expression increased in inflamed lung tissue, providing in vivo evidence for the link between hypothiocyanous acid metabolism by TrxR and the promotion of selective biocide of pathogens. SCN treatment both suppressed inflammation and improved host defense, suggesting that nebulized SCN may have important therapeutic utility in diseases of both chronic airway inflammation and persistent bacterial infection, such as CF.

Indexed as

Administration, InhalationAnimalsAnti-Bacterial AgentsAnti-Inflammatory AgentsCell LineCystic FibrosisDrug Evaluation, PreclinicalFemaleLungMaleMice, Inbred C57BLOxidative StressPneumonia, BacterialPseudomonas aeruginosaPseudomonas InfectionsThiocyanatesAnti-Bacterial AgentsAnti-Inflammatory AgentsthiocyanateThiocyanatesThioredoxin-Disulfide Reductaseantioxidantglutathione sulfonamidehypothiocyanous acidinnate immunitynebulization

Identifiers

PMID25490247
PMCPMC4566044
OpenAlexW2014892346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.